Journal
BIOMOLECULES
Volume 11, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/biom11020236
Keywords
RAS oncogene; RAS signaling networks; RAS in human cancer; targeting RAS; computational modeling; personalized therapies
Categories
Funding
- Science Foundation Ireland [16/FRL/3886, CDA 15/CDA/3495, 18/SPP/3522, 14/IA/2395]
Ask authors/readers for more resources
RAS oncogenes, commonly mutated in human cancers, control various cellular functions and their signaling is altered in over half of human cancers. Recent efforts in detailed molecular studies, large-scale omics studies, and computational modeling are providing a comprehensive understanding of RAS signaling, paving the way for new mechanism-based therapies for RAS mutated cancers.
RAS oncogenes are among the most commonly mutated proteins in human cancers. They regulate a wide range of effector pathways that control cell proliferation, survival, differentiation, migration and metabolic status. Including aberrations in these pathways, RAS-dependent signaling is altered in more than half of human cancers. Targeting mutant RAS proteins and their downstream oncogenic signaling pathways has been elusive. However, recent results comprising detailed molecular studies, large scale omics studies and computational modeling have painted a new and more comprehensive portrait of RAS signaling that helps us to understand the intricacies of RAS, how its physiological and pathophysiological functions are regulated, and how we can target them. Here, we review these efforts particularly trying to relate the detailed mechanistic studies with global functional studies. We highlight the importance of computational modeling and data integration to derive an actionable understanding of RAS signaling that will allow us to design new mechanism-based therapies for RAS mutated cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available